Predicting HCC Response to Multikinase Inhibitors With In Vivo Cirrhotic Mouse Model for Personalized Therapy
Sign Up to like & getrecommendations! Published in 2020 at "Cellular and Molecular Gastroenterology and Hepatology"
DOI: 10.1016/j.jcmgh.2020.12.009
Abstract: Background & Aims Hepatocellular carcinoma (HCC) arises in a cirrhotic, pro-angiogenic microenvironment. Inhibiting angiogenesis is a key mode of action of multikinase inhibitors and current non-cirrhotic models are unable to predict treatment response. We present… read more here.
Keywords: cirrhotic model; response; multikinase inhibitors; model ... See more keywords
Significance and Prognostic Value of The Coagulation Profile in Patients with Glioblastoma: Implications for Personalized Therapy.
Sign Up to like & getrecommendations! Published in 2019 at "World neurosurgery"
DOI: 10.1016/j.wneu.2018.09.177
Abstract: BACKGROUND Coagulation is an important aspect of the vascular microenvironment in which brain tumors evolve. Patients with tumor often show aberrant coagulation and fibrinolysis activation. In particular, glioblastoma (GBM), the most aggressive primary brain tumor,… read more here.
Keywords: coagulation; patients gbm; significance; coagulation profile ... See more keywords
Developments in personalized therapy for metastatic renal cell carcinoma
Sign Up to like & getrecommendations! Published in 2022 at "Expert Review of Anticancer Therapy"
DOI: 10.1080/14737140.2022.2075347
Abstract: ABSTRACT Introduction Immune checkpoint inhibitors (ICIs) have made an appearance in clinical practice, and the treatment outcome of metastatic renal cell cancer (mRCC) has dramatically improved as a result. Currently, most patients are treated with… read more here.
Keywords: personalized therapy; renal cell; metastatic renal; combination ... See more keywords
Personalized therapy in pediatric high-risk B-cell acute lymphoblastic leukemia
Sign Up to like & getrecommendations! Published in 2020 at "Therapeutic Advances in Hematology"
DOI: 10.1177/2040620720927575
Abstract: Although cure rates for pediatric acute lymphoblastic leukemia (ALL) have now risen to more than 90%, subsets of patients with high-risk features continue to experience high rates of treatment failure and relapse. Recent work in… read more here.
Keywords: risk; high risk; lymphoblastic leukemia; acute lymphoblastic ... See more keywords
Whole-exome analysis in osteosarcoma to identify a personalized therapy
Sign Up to like & getrecommendations! Published in 2017 at "Oncotarget"
DOI: 10.18632/oncotarget.19010
Abstract: Osteosarcoma is the most common pediatric primary non-hematopoietic bone tumor. Survival of these young patients is related to the response to chemotherapy and development of metastases. Despite many advances in cancer research, chemotherapy regimens for… read more here.
Keywords: exome analysis; osteosarcoma; identify personalized; whole exome ... See more keywords
3D Printed Mini-Floating-Polypill for Parkinson’s Disease: Combination of Levodopa, Benserazide, and Pramipexole in Various Dosing for Personalized Therapy
Sign Up to like & getrecommendations! Published in 2022 at "Pharmaceutics"
DOI: 10.3390/pharmaceutics14050931
Abstract: Therapy for Parkinson’s disease is quite challenging. Numerous drugs are available for symptomatic treatment, and levodopa (LD), in combination with a dopa decarboxylase inhibitor (e.g., benserazide (BZ)), has been the drug of choice for years.… read more here.
Keywords: personalized therapy; parkinson disease; combination; therapy ... See more keywords